Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University Hospital Tuebingen |
---|---|
Information provided by: | University Hospital Tuebingen |
ClinicalTrials.gov Identifier: | NCT00696956 |
The study will be performed as a randomized, double blind trial (in respect of the primary end point) with treatment of the stenotic lesion using uncoated PTA-catheters as control group. 114 patients will be included in the trial at about 5 study centers. Follow-up includes control angiography after 6 and 18 months and clinical follow-up examinations up to 18 months. Primary objective:
Efficacy of paclitaxel coated PTA balloons in inhibiting restenosis of below the knee arteries (late lumen loss)
Secondary objective:
Various angiographic and clinical efficacy measures, safety and tolerance of pacli-taxel coated PTA balloons in inhibiting restenosis of below the knee arteries Descriptive statistics, comparison by t-test, chi-square test for binary events 10.1 Descriptive statistics As far as applicable descriptive statistics will be applied to data and will be referring to individual changes versus baseline (predilatation or immediately postdilatation). The groups will be compared to each other testing the statistical significance of differences (p ≤ 0.05). Con-tinuous data will be expressed as mean ± standard deviation.
Categorical variables will be compared using the chi-squared test, and continuous variables will be compared using Student's t test or ANOVA analysis.
In addition to the assessment of the primary endpoint and the secondary endpoints a multi-variate analysis to investigate the influence of risk factors on the interventional outcome (interventional success, early restenosis/occlusion, LLL, stent integrity) and clinical outcomes will be performed. For this analysis the following factors will be considered: age, diabetes, neurological status (only Rutherford 5), lesion length, grade of dissection and calcification, reststenosis, number of run-off vessels, stent administration in the index lesion(s).
10.2 Estimated number of patients The primary endpoint of the study is late lumen loss (LLL) at 6 months evaluated by quantitative angiography. Because no data according this endpoint are available for both the control group and the group which will be treated with the paclitaxel coated balloon an assumption according the LLL at 6 months was made according the expectations of the principle investigator. An estimate for LLL as % of MLD in the control group is 50% and in the drug coated balloon group 30 %. The standard deviation is calculated to be 30% of LLL. A sample size of 37 patients in each group will allow the detection of a statistically significant difference (p<0.05) with 80% power. Based on the "Below study" which enrolled patients with comparable arterial lesions in Tuebingen and the data of the Basil study, it is estimated that 35% of the patients who will be enrolled in the study will not be available for follow-up investigations in order to calculate the MLD.
In order to meet a statistical endpoint a total of 114 patients will be enrolled.
Condition | Intervention | Phase |
---|---|---|
Atherosclerosis Restenosis Limb Ishemia |
Device: Balloon angioplasty (uncoated conventional balloon) Device: Balloon angioplasty (conventional but coated with 3 µg/mm2 paclitaxel) |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Paclitaxel Coated Balloons for Prevention of Restenosis in Small Arteries Below the Knee Compared to Angioplasty Using Uncoated Balloons |
Estimated Enrollment: | 114 |
Study Start Date: | April 2008 |
Estimated Study Completion Date: | April 2011 |
Estimated Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Placebo Comparator
Normal balloon for balloon angioplasty (Submarine, Ampherion Deep by Invatec)
|
Device: Balloon angioplasty (uncoated conventional balloon)
endovascular therapy
|
2: Active Comparator
Paclitaxel coated balloon (same balloon like in the control group, but coated with 3 µg/mm2 Paclitaxel)
|
Device: Balloon angioplasty (conventional but coated with 3 µg/mm2 paclitaxel)
endovascular therapy
|
Ages Eligible for Study: | 18 Years to 95 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Gunnar Tepe, MD | 49-707-129 ext 83371 | gunnar.tepe@med.uni-tuebingen.de |
Germany, B | |
Jüdisches Krankenhaus Berlin | Active, not recruiting |
Berlin, B, Germany, 10001 | |
Charite Berlin | Active, not recruiting |
Berlin, B, Germany, 10001 | |
Germany, BW | |
University of Tuebingen | Recruiting |
Tuebingen, BW, Germany, 72076 | |
Contact: Gunnar Tepe, MD 49-707-129 ext 83371 gunnar.tepe@med.uni-tuebingen.de | |
Principal Investigator: Gunnar Tepe, MD | |
Herzzentrum Bad Krozingen | Recruiting |
Bad Krozingen, BW, Germany, 76551 | |
Contact: Thomas Zeller, MD thomas.zeller@herzzentrum.de | |
Germany, MP | |
University of Rostock | Active, not recruiting |
Rostock, MP, Germany, 01065 |
Responsible Party: | Universtiy of Tuebingen ( Prof. Dr. med. Gunnar Tepe ) |
Study ID Numbers: | Pac-3, Pac-3 |
Study First Received: | June 10, 2008 |
Last Updated: | June 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00696956 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices; United States: Institutional Review Board |
local drug delivery balloon angioplasty safety and tolerance of paclitaxel coated PTA balloons |
in inhibiting restenosis of below the knee arteries Efficacy of paclitaxel coated PTA balloons in inhibiting restenosis of below the knee arteries (late lumen loss) |
Arterial Occlusive Diseases Atherosclerosis Paclitaxel Vascular Diseases Arteriosclerosis |
Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Therapeutic Uses Mitosis Modulators Tubulin Modulators |
Cardiovascular Diseases Antimitotic Agents Antineoplastic Agents, Phytogenic Pharmacologic Actions |